HOME >> BIOLOGY >> NEWS
New multiple myeloma treatment induced total remission in 33 percent of patients

A study, lead by Dr. Laura Rosiol, researcher of the Haematooncology Group of Hospital Clnic-IDIBAPS (Barcelona) in collaboration with Dr Joan Blade, researcher in the same group, administered alternately two drugs (Bortezomid and Dexamethasone) before conducting autologous bone marrow transplantations. The aim of this second phase trial was to assess the treatments overall response rate, its toxicity in patients, the possibility of recovery of innate stem cells, and the response kinetics which is calculated by measuring M-protein concentrations in serum and urine. M-protein is associated with myeloma presence.

This research work, conducted in the frame of the PETHEMA network, has been coordinated by Hospital Clnic de Barcelona and had the participation of eight more Spanish hospitals: Hospital Germans Trias i Pujol, Hospital Clnico Salamanca, Hospital de Sant Pau, Hospital Clnico de Madrid, Hospital La Princesa, Hospital 12 de Octubre and Hospital La Fe. A total of 40 patients between 41 and 65 years with newly diagnosed multiple myeloma participated in this study. All of them underwent six treatment cycles with a 10-day break between each, and were administered Bortezomid or Dexamethasone alternately.

This study has showed very relevant facts. The first notable fact is that there was a global reduction of M-protein concentration in both urine and plasma, reflecting a global reduction of tumour cells. Thus, a highly efficient anti-myeloma effect was observed, and the post autologous transplantation response index was favourable: a 94% response, one third of which (33%) was of complete response (CR) and 22% was a very good partial response (VGPR).

Another surprising result was the speed at which the effect was achieved i.e. the highest reduction in M-protein was detected within the first four treatment cycles. It should be mentioned that the first two cycles already caused an 82% reduction. These results set the base for furt
'"/>

Contact: Anna Ramon
comunicacio@clinic.ub.es
34-932-275-700
IDIBAPS - Institut d'Investigacions Biomdiques August Pi i Sunyer
4-Jun-2007


Page: 1 2

Related biology news :

1. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
2. Research teams uncover risk genes for multiple sclerosis
3. First new multiple sclerosis gene found in 30 years
4. After a decades-long search, scientists identify new genetic risk factors for multiple sclerosis
5. Risk genes for multiple sclerosis uncovered
6. Obesity found to be a risk factor for multiple myeloma
7. Kaposi sarcoma arises independently from multiple cells
8. New collaborative research reveals chimpanzees can sustain multiple-tradition cultures
9. Testosterone may help men with multiple sclerosis
10. New imaging approach promises insights into multiple sclerosis
11. Study identifies multiple genetic risk factors for prostate cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/11/2019)... ... November 11, 2019 , ... MicroGenDX, the world leader in ... in the award-winning study “Next Generation Sequencing for the Diagnosis of Periprosthetic Knee ... processed samples using Next Generation DNA Sequencing to examine the ability of NGS ...
(Date:11/6/2019)... Va. (PRWEB) , ... November 06, 2019 , ... ... today that Donald Stanski, MD, a senior pharmaceutical industry executive with expertise in ... and simulation for drug and disease strategic data analytics, has joined the firm ...
(Date:11/5/2019)... WA (PRWEB) , ... November 05, 2019 , ... ... & Amato Dentistry, providing state-of-the-art cosmetic and restorative dentistry to Seattle, WA, including ... her Doctor of Dental Surgery degree from the University of Washington, Dr. Kopp ...
Breaking Biology News(10 mins):
(Date:11/27/2019)... ... November 25, 2019 , ... Silony Medical, a medical ... and navigated surgery in the UK. The procedure was performed in the UK’s ... Syed Aftab and Dr. Alexander Montgomery. The surgery, which took place on July ...
(Date:11/20/2019)... ... November 20, 2019 , ... Defense and ... microturbine electrical power generation units from 2019-2028. The value of this production is ... of 3,821 units worth $569 million. , Reference to 2017 is important, ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... R&D, today announced that Immatics Biotechnologies , a clinical-stage biopharmaceutical company ... to streamline their R&D operations related to the discovery and development of ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... to educate Americans about the deadly healthcare-associated infection C. diff. The campaign, ... of the epidemic, which kills at least 30,000 people in the U.S. each ...
Breaking Biology Technology:
Cached News: